Chris Shibutani
Stock Analyst
(2.19)
# 960
Out of 4,648 analysts
99
Total ratings
43.24%
Success rate
-3.44%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $376.80 | -19.85% | 4 | Nov 1, 2024 | |
| ALKS Alkermes | Maintains: Buy | $32 → $30 | $26.59 | +12.82% | 6 | Oct 25, 2024 | |
| ERAS Erasca | Maintains: Buy | $3 → $3.5 | $2.87 | +21.95% | 6 | Oct 25, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $27.20 | +87.50% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $158.24 | -2.05% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $5.70 | -29.82% | 8 | Jul 12, 2024 | |
| RVNC Revance Therapeutics | Maintains: Neutral | $9 → $8 | $5.81 | +37.69% | 5 | May 13, 2024 | |
| OGN Organon & Co. | Maintains: Neutral | $18 → $20 | $16.92 | +18.20% | 5 | May 6, 2024 | |
| LLY Eli Lilly | Maintains: Neutral | $650 → $723 | $806.14 | -10.31% | 6 | Apr 11, 2024 | |
| SDGR Schrödinger | Maintains: Neutral | $29 → $26 | $18.24 | +42.54% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $113 → $100 | $108.97 | -8.23% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $120.53 | +26.94% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $200.47 | -13.70% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.33 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $4 → $1.25 | $0.81 | +54.82% | 3 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $55.45 | +24.44% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $18.94 | +58.39% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $19.36 | -32.85% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $55.87 | -58.83% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $2.15 | +2,225.58% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $47.07 | +10.47% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $27.76 | +116.14% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $17.77 | +1.29% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $20 | $5.01 | +299.20% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $5.16 | +229.46% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.58 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.89 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.95 | - | 4 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $16.97 | - | 3 | May 2, 2017 |
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $376.80
Upside: -19.85%
Alkermes
Oct 25, 2024
Maintains: Buy
Price Target: $32 → $30
Current: $26.59
Upside: +12.82%
Erasca
Oct 25, 2024
Maintains: Buy
Price Target: $3 → $3.5
Current: $2.87
Upside: +21.95%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $27.20
Upside: +87.50%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $158.24
Upside: -2.05%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $5.70
Upside: -29.82%
Revance Therapeutics
May 13, 2024
Maintains: Neutral
Price Target: $9 → $8
Current: $5.81
Upside: +37.69%
Organon & Co.
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $16.92
Upside: +18.20%
Eli Lilly
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $806.14
Upside: -10.31%
Schrödinger
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $18.24
Upside: +42.54%
Feb 28, 2024
Maintains: Neutral
Price Target: $113 → $100
Current: $108.97
Upside: -8.23%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $120.53
Upside: +26.94%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $200.47
Upside: -13.70%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $1.33
Upside: -
Nov 3, 2023
Maintains: Sell
Price Target: $4 → $1.25
Current: $0.81
Upside: +54.82%
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $55.45
Upside: +24.44%
Oct 11, 2023
Initiates: Buy
Price Target: $30
Current: $18.94
Upside: +58.39%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $19.36
Upside: -32.85%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $55.87
Upside: -58.83%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $2.15
Upside: +2,225.58%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $47.07
Upside: +10.47%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $27.76
Upside: +116.14%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $17.77
Upside: +1.29%
May 24, 2022
Maintains: Buy
Price Target: $23 → $20
Current: $5.01
Upside: +299.20%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $5.16
Upside: +229.46%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.58
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.89
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $2.95
Upside: -
May 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $16.97
Upside: -